Alnylam Pharmaceuticals ALNY

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$3.61 (-1.45%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $244.52

  • Market Cap

    $31.65 Billion

  • Price-Earnings Ratio

    -112.17

  • Total Outstanding Shares

    129.46 Million Shares

  • Total Employees

    2,230

  • Dividend

    No dividend

  • IPO Date

    May 28, 2004

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    675 west kendall street, Cambridge, MA, 02142

  • Homepage

    https://www.alnylam.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

January 1, 2024 to December 31, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-116.84 Million
Net Cash Flow From Operating Activities$-8.31 Million
Net Cash Flow From Investing Activities$-116.84 Million
Net Cash Flow$153.77 Million
Net Cash Flow From Financing Activities$294.16 Million
Exchange Gains/Losses$-15.24 Million

Income Statement

January 1, 2024 to December 31, 2024
MetricValue
Income Tax Expense/Benefit, Current$7.54 Million
Income/Loss From Continuing Operations After Tax$-278.16 Million
Gross Profit$1.94 Billion
Net Income/Loss Available To Common Stockholders, Basic$-278.16 Million
Selling, General, and Administrative Expenses$975.53 Million
Basic Earnings Per Share$-2.18

Comprehensive Income

January 1, 2024 to December 31, 2024
MetricValue
Comprehensive Income/Loss$-289.30 Million
Other Comprehensive Income/Loss$-11.14 Million
Other Comprehensive Income/Loss Attributable To Parent$-11.14 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss Attributable To Parent$-289.30 Million

Balance Sheet

January 1, 2024 to December 31, 2024
MetricValue
Other Current Assets$3.22 Billion
Inventory$78.51 Million
Assets$4.24 Billion
Noncurrent Assets$944.70 Million
Current Assets$3.30 Billion
Equity Attributable To Noncontrolling Interest$0

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ALNY from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.